| Literature DB >> 35142380 |
Jun Kido1,2, Johannes Häberle3, Keishin Sugawara1, Toju Tanaka4, Masayoshi Nagao4, Takaaki Sawada1,2, Yoichi Wada5, Chikahiko Numakura6, Kei Murayama7, Yoriko Watanabe8,9, Kanako Kojima-Ishii10, Hideo Sasai11, Kiyotaka Kosugiyama12, Kimitoshi Nakamura1,2.
Abstract
Citrin deficiency is an autosomal recessive disorder caused by mutations in the SLC25A13 gene. The disease can present with age-dependent clinical manifestations: neonatal intrahepatic cholestasis by citrin deficiency (NICCD), failure to thrive, and dyslipidemia by citrin deficiency (FTTDCD), and adult-onset type II citrullinemia (CTLN2). As a nationwide study to investigate the clinical manifestations, medical therapy, and long-term outcome in Japanese patients with citrin deficiency, we collected clinical data of 222 patients diagnosed and/or treated at various different institutions between January 2000 and December 2019. In the entire cohort, 218 patients were alive while 4 patients (1 FTTDCD and 3 CTLN2) had died. All patients <20 years were alive. Patients with citrin deficiency had an increased risk for low weight and length at birth, and CTLN2 patients had an increased risk for growth impairment during adolescence. Liver transplantation has been performed in only 4 patients (1 NICCD, 3 CTLN2) with a good response thereafter. This study reports the diagnosis and clinical course in a large cohort of patients with citrin deficiency and suggests that early intervention including a low carbohydrate diet and MCT supplementation can be associated with improved clinical course and long-term outcome.Entities:
Keywords: CTLN2; Citrullinemia type 2; MCT; NICCD; citrulline; long-term survival
Mesh:
Substances:
Year: 2022 PMID: 35142380 DOI: 10.1002/jimd.12483
Source DB: PubMed Journal: J Inherit Metab Dis ISSN: 0141-8955 Impact factor: 4.982